SUN Pharmaceutical Industries Limited — Ketorolac Exporter Profile
Indian Pharmaceutical Exporter · #2 for Ketorolac · $4.8M export value · DGFT Verified
SUN Pharmaceutical Industries Limited is the #2 Indian exporter of Ketorolac with $4.8M in export value and 95 verified shipments. SUN Pharmaceutical Industries Limited holds a 4.1% market share in Ketorolac exports across 3 countries. The company exports 118 pharmaceutical products worth $979.8M across 25 therapeutic categories.
SUN Pharmaceutical Industries Limited — Ketorolac Export Profile: Buyers & Destinations
Where Does SUN Pharmaceutical Industries Limited Export Ketorolac?
| Country | Value | Shipments | Share |
|---|---|---|---|
| RUSSIA | $4.2M | 87 | 92.7% |
| IRAN | $218.7K | 6 | 4.8% |
| UNITED STATES | $112.0K | 7 | 2.5% |
| NIGERIA | $149 | 1 | 0.0% |
SUN Pharmaceutical Industries Limited exports Ketorolac to 4 countries. The largest destination is RUSSIA accounting for 92.7% of SUN Pharmaceutical Industries Limited's Ketorolac shipments, followed by IRAN (4.8%) and UNITED STATES (2.5%). These destinations reflect SUN Pharmaceutical Industries Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Ketorolac from SUN Pharmaceutical Industries Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| AO RANBAXY | RUSSIA | $2.7M | 56 |
| AO "RANBAXY" | RUSSIA | $1.6M | 34 |
| SUN PHARMACEUTICAL INDUSTRIES,INC. | UNITED STATES | $112.0K | 7 |
| AO RANBAXY - | RUSSIA | $59.9K | 2 |
| MULTI SMARTLINE RESOURCES LTD. | NIGERIA | $149 | 1 |
| REPRESENTATIVE OFFICE OF SUN | RUSSIA | $24 | 1 |
SUN Pharmaceutical Industries Limited supplies Ketorolac to 6 buyers globally. The largest buyer is AO RANBAXY (RUSSIA), followed by AO "RANBAXY" (RUSSIA) and SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Ketorolac Export Value and How Much Does SUN Pharmaceutical Industries Limited Contribute?
India exported $49.5M worth of Ketorolac through 2,961 shipments from 351 suppliers to 124 countries, serving 638 buyers globally. SUN Pharmaceutical Industries Limited contributes $4.8M to this total, accounting for 4.1% of India's Ketorolac exports. SUN Pharmaceutical Industries Limited ships Ketorolac to 4 countries through 6 buyers.
What Is the Average Shipment Value for SUN Pharmaceutical Industries Limited's Ketorolac Exports?
SUN Pharmaceutical Industries Limited's average Ketorolac shipment value is $50.0K per consignment, based on 95 shipments totaling $4.8M. The largest destination is RUSSIA (92.7% of SUN Pharmaceutical Industries Limited's Ketorolac exports).
How Does SUN Pharmaceutical Industries Limited Compare to Other Indian Ketorolac Exporters?
SUN Pharmaceutical Industries Limited ranks #2 among 351 Indian Ketorolac exporters with a 4.1% market share. The top 3 exporters are CAPLIN STERILES LIMITED ($11.5M), GLAND PHARMA LIMITED ($10.6M), GLAND PHARMA LTD ($9.7M). SUN Pharmaceutical Industries Limited processed 95 shipments to 3 destination countries.
What Ketorolac Formulations Does SUN Pharmaceutical Industries Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| KETOROLAC TROMETAMOL MD TABS 10 MG (KETANOV TABS) (PACK :BOX20S) | $218.7K | 6 |
| KETANOV TABLETS 10MG PACK : BOX20S BATCH: DFE8576A, DFE8633A, DFF0021A EACH TABCONTS KETOROLAC TROMETHAMINE 10 MGPCS | $150.0K | 3 |
| KETANOV TABLETS 10MG PACK:BOX20S BATCH:DFF0457A, DFF0458A, DFF0521A EACH TAB CONTS. KETOROLAC TROMETHAMINE 10MGPCS | $150.0K | 3 |
| KETANOV TABLETS 10MG PACK:BOX20S BATCH:DFF1838A, DFF1839A, DFF1898A EACH TAB CONTS. KETOROLAC TROMETHAMINE 10 MG | $150.0K | 3 |
| KETANOV TABLETS 10MG PACK:BOX20S BATCH:DFF1897A, DFF2060A, DFF2061A, DFF2061B EACH TAB CONTS. KETOROLAC TROMETHAMINE 10 | $150.0K | 3 |
| Ketanov MD Tablet 10mg EACH TABELT CONTAINS KETOROLAC TROMETAMOL PH.EUR 10 MG (PACK :Box20s) (KETOROLAC TROMETAMOL MOUTH | $150.0K | 3 |
| KETOROLAC TROMETHAMINE OPHTHALMIC SOLUTI | $112.0K | 7 |
| KETANOV TABLETS 10MG PACK:BOX10X10s BATCH:DFF7950A, DFF7951A EACH TAB CONTS.KETOROLAC TROMETHAMINE 10MG | $100.0K | 2 |
| KETANOV TABLETS 10MG PACK:BOX20s BATCH:DFF3061A EACH TAB CONTS. KETOROLAC TROMETHAMINE 10MG | $88.3K | 3 |
| KETANOV TABLETS 10MG PACK Box20s Batch DFE0572B DFE0573A DFE0574A EACH TAB CONTS KETOROLAC TROMETHAMINE 10 MG | $50.0K | 1 |
SUN Pharmaceutical Industries Limited exports 77 distinct Ketorolac formulations including tablets, capsules, syrups, and combination drugs. The top formulation is KETOROLAC TROMETAMOL MD TABS 10 MG (KETANOV TABS) (PACK :BOX with 6 shipments worth $218.7K.
Regulatory Requirements: Exporting Ketorolac to Key Markets
What SUN Pharmaceutical Industries Limited must comply with to export Ketorolac to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does SUN Pharmaceutical Industries Limited Compare to Nearest Ketorolac Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | GLAND PHARMA LIMITED | $10.6M | 212 | 5 | $50.0K |
| 3 | GLAND PHARMA LTD | $9.7M | 193 | 5 | $50.0K |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ★ | $4.8M | 95 | 3 | $50.0K |
| 4 | ALEMBIC PHARMACEUTICALS LIMITED | $3.5M | 70 | 1 | $50.0K |
| 6 | MICRO LABS LIMITED | $3.0M | 60 | 10 | $50.0K |
SUN Pharmaceutical Industries Limited ranks #2 among 351 Indian Ketorolac exporters. Average shipment value of $50.0K compared to the market average of $141.1K. The closest competitors by value are GLAND PHARMA LIMITED and GLAND PHARMA LTD.
Which Indian Ports Ship Ketorolac Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 337 | 11.4% |
| SAHAR AIR | 229 | 7.7% |
| NHAVA SHEVA SEA (INNSA1) | 227 | 7.7% |
| HYDERABAD ICD (INSNF6) | 127 | 4.3% |
| HYDERABAD AIR | 93 | 3.1% |
| DELHI AIR | 92 | 3.1% |
| DELHI AIR CARGO ACC (INDEL4) | 75 | 2.5% |
| HYDERABAD ICD | 74 | 2.5% |
Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Ketorolac Exports
Sun Pharma's export operations, valued at $979.8 million, are significantly influenced by current geopolitical events. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to Europe and North Africa. Major shipping lines have imposed 'Emergency Risk Surcharges,' increasing freight costs and extending transit times by 10–15 days. These delays pose risks to the integrity of time-sensitive and temperature-controlled pharmaceutical shipments. (pharmaceuticalcommerce.com)
In the United States, policy shifts towards domestic manufacturing and the imposition of tariffs on imported pharmaceuticals have created challenges for Indian exporters. Sun Pharma, which supplies a substantial portion of generics to the U.S. market, faces potential reductions in export volumes due to these protectionist measures. The company is exploring strategies such as establishing local partnerships and investing in U.S.-based manufacturing to mitigate these impacts. (odrindia.in)
The European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) introduces additional compliance requirements for exporters. Sun Pharma must adapt to these regulations to maintain its market presence in the EU, necessitating investments in sustainable manufacturing practices and comprehensive reporting mechanisms. (sgeexport.com)
SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains a critical focus for Sun Pharma. The company has encountered challenges with the U.S. FDA, including import alerts and non-compliance letters for certain facilities. Addressing these issues involves implementing corrective actions and awaiting reinspection to resume full operations. (business-standard.com)
Globally, the pharmaceutical industry faces increasing scrutiny regarding quality standards. Sun Pharma's commitment to adhering to Good Manufacturing Practices (GMP) and other regulatory requirements is essential to maintain its export licenses and market reputation. Continuous investment in quality control systems and compliance infrastructure is imperative to navigate the evolving regulatory landscape.
About SUN Pharmaceutical Industries Limited
SUN Pharmaceutical Industries Limited exports 118 products worth $979.8M. Beyond Ketorolac, top products include Strip, Esomeprazole, Magnesium, Calcium, Omeprazole. View the complete SUN Pharmaceutical Industries Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Ketorolac — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Ketorolac shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: SUN Pharmaceutical Industries Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 101 individual customs records matching SUN Pharmaceutical Industries Limited exporting Ketorolac, covering 77 formulations to 4 countries via 6 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 124+ countries, 638+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Ketorolac Export Data from SUN Pharmaceutical Industries Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for SUN Pharmaceutical Industries Limited's Ketorolac exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
SUN Pharmaceutical Industries Limited
Full Company Profile →
118 products · $979.8M total trade · 25 categories
Ketorolac Stats
Company Overview
Top Products by SUN Pharmaceutical Industries Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for SUN Pharmaceutical Industries Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ketorolac. For current shipment-level data, contact TransData Nexus.